PROK
ProKidneyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The favorable read-through from the May 15, 2026 8-K and press release is that ProKidney preserved its core thesis after earnings: PROACT 1 enrollment is still targeted for mid-2026, Q2 2027 topline timing was reiterated, FDA alignment on the accelerated-approval surrogate endpoint remains intact, and management still guides to funding into mid-2027. For a low-coverage pre-revenue biotech, simple preservation of timeline and runway matters more than quarterly revenue.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Clinical and regulatory risk remains dominant because rilparencel's value is tied to one ongoing Phase 3 program and the FDA could still require additional studies or reject the surrogate-endpoint path.
Momentum
47
Value
41
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.90 · Bull $3.20 · Bear $0.85
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $6.25
Why
Momentum47 · Δ7d -
Value41 · Δ7d +0.1
Sentiment49 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
47
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
49
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 47.3 / Value 41.1 / Sentiment 49.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$558.81M
Beta
1.82
Shares Out
300.83M
P/E (TTM) · Derived
-3.0
P/S (TTM)
865.30
P/FCF (TTM) · Derived
-1.65
Rev YoY
-
EPS YoY
+14.1%
Gross Margin
-
Op Margin
-23011.7%
Net Debt
-$358.19M
Current Ratio
10.32
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology